Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.37 |
| ▸ | CTSD | P07339 | 13/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14156529 | 0.88 | BACE1 (0.37) | BACE1CTSD | |
| SCHEMBL4825336 | 0.83 | BACE1 (0.40) | BACE1CTSDBACE2 | |
| SCHEMBL4825332 | 0.83 | BACE1 (0.40) | BACE1CTSDBACE2 | |
| SCHEMBL14163605 | 0.80 | KLK5 (0.43) | BACE1CTSD | |
| SCHEMBL5566679 | 0.80 | NPC1 (0.44) | BACE1 | |
| SCHEMBL5566685 | 0.80 | NPC1 (0.44) | BACE1 | |
| SCHEMBL5566692 | 0.80 | NPC1 (0.44) | BACE1 | |
| SCHEMBL4826102 | 0.79 | BACE1 (0.43) | BACE1CTSDBACE2 | |
| SCHEMBL3172234 | 0.78 | BACE1 (0.42) | BACE1CTSDBACE2 | |
| SCHEMBL3353623 | 0.78 | BACE1 (0.42) | BACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388118-B2 | Amine 1,2- and 1,3-diol compounds | PHAMACIA & UPJOHN COMPANY LLC (US) | 2008-06-17 | — | — | US | disclosed |
| EP-1453792-B1 | AMINE 1,2- AND 1,3-DIOL COMPOUNDS AND THEIR USE FOR TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARM INC (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20040039064-A1 | Amine 1,2- and 1,3-diol compounds | PHARMACIA & UPJOHN COMPANY LLC | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039064-A1 | Amine 1,2- and 1,3-diol compounds | BACE1, BACE2, APP | BACE1 1/4885CTSD 171/4885BACE2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.